 Robert Scheinman
Concepts (433)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthritis, Rheumatoid | 11 | 2025 | 1167 | 1.690 |
Why?
| | NF-kappa B | 18 | 2010 | 691 | 1.130 |
Why?
| | Arthritis, Experimental | 7 | 2020 | 147 | 0.940 |
Why?
| | Complement System Proteins | 5 | 2024 | 327 | 0.890 |
Why?
| | Complement Activation | 8 | 2025 | 410 | 0.880 |
Why?
| | Nanoparticles | 7 | 2025 | 478 | 0.710 |
Why?
| | Complement C3 | 6 | 2024 | 209 | 0.590 |
Why?
| | Tumor Necrosis Factor-alpha | 6 | 2012 | 1242 | 0.580 |
Why?
| | T-Lymphocytes | 7 | 2012 | 1993 | 0.520 |
Why?
| | Erythropoietin | 2 | 2008 | 95 | 0.510 |
Why?
| | Drug Carriers | 2 | 2017 | 127 | 0.470 |
Why?
| | RNA, Small Interfering | 4 | 2020 | 622 | 0.470 |
Why?
| | Antirheumatic Agents | 2 | 2020 | 292 | 0.450 |
Why?
| | I-kappa B Proteins | 5 | 2002 | 81 | 0.440 |
Why?
| | Macrophages | 6 | 2019 | 1544 | 0.440 |
Why?
| | Polyethylene Glycols | 6 | 2025 | 639 | 0.440 |
Why?
| | Complement Pathway, Mannose-Binding Lectin | 3 | 2020 | 26 | 0.430 |
Why?
| | Complement Inactivating Agents | 2 | 2025 | 63 | 0.380 |
Why?
| | Doxorubicin | 5 | 2025 | 362 | 0.380 |
Why?
| | STAT1 Transcription Factor | 1 | 2011 | 73 | 0.360 |
Why?
| | Interferon-gamma | 2 | 2012 | 789 | 0.360 |
Why?
| | Apoptosis | 6 | 2020 | 2552 | 0.360 |
Why?
| | Rheumatology | 1 | 2012 | 118 | 0.340 |
Why?
| | Interleukin-2 | 1 | 2012 | 455 | 0.340 |
Why?
| | Ferrosoferric Oxide | 3 | 2019 | 27 | 0.340 |
Why?
| | Liposomes | 4 | 2025 | 220 | 0.330 |
Why?
| | Transcription, Genetic | 5 | 2020 | 1455 | 0.320 |
Why?
| | Osteoarthritis | 1 | 2012 | 185 | 0.320 |
Why?
| | Mannose-Binding Protein-Associated Serine Proteases | 3 | 2020 | 20 | 0.310 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2009 | 87 | 0.300 |
Why?
| | Animals | 35 | 2025 | 36836 | 0.300 |
Why?
| | Complement Factor D | 2 | 2020 | 30 | 0.290 |
Why?
| | Fibrosarcoma | 1 | 2008 | 22 | 0.290 |
Why?
| | N-Acetyllactosamine Synthase | 1 | 2007 | 1 | 0.270 |
Why?
| | Protein Modification, Translational | 1 | 2007 | 2 | 0.270 |
Why?
| | Dexamethasone | 4 | 2000 | 368 | 0.270 |
Why?
| | Butyrates | 1 | 2008 | 61 | 0.270 |
Why?
| | Coenzymes | 1 | 2007 | 19 | 0.270 |
Why?
| | Nanomedicine | 2 | 2025 | 47 | 0.270 |
Why?
| | Protein Engineering | 1 | 2008 | 97 | 0.260 |
Why?
| | Manganese | 1 | 2007 | 62 | 0.260 |
Why?
| | Receptors, Glucocorticoid | 2 | 2000 | 155 | 0.260 |
Why?
| | Signal Transduction | 8 | 2020 | 5077 | 0.250 |
Why?
| | DNA-Binding Proteins | 7 | 2019 | 1501 | 0.240 |
Why?
| | GTP-Binding Proteins | 1 | 2006 | 161 | 0.240 |
Why?
| | Single-Domain Antibodies | 1 | 2025 | 14 | 0.240 |
Why?
| | Nuclear Matrix | 1 | 2005 | 7 | 0.240 |
Why?
| | Lymphocyte Activation | 3 | 2004 | 1150 | 0.240 |
Why?
| | Mice | 20 | 2025 | 17758 | 0.230 |
Why?
| | beta-Arrestins | 1 | 2024 | 15 | 0.230 |
Why?
| | Complement Factor H | 1 | 2025 | 75 | 0.220 |
Why?
| | Receptors, Complement 3b | 2 | 2023 | 84 | 0.220 |
Why?
| | Synovial Membrane | 1 | 2025 | 117 | 0.220 |
Why?
| | Transcription Factor AP-1 | 3 | 2000 | 92 | 0.220 |
Why?
| | Molecular Docking Simulation | 1 | 2024 | 113 | 0.220 |
Why?
| | Rats | 12 | 2025 | 5639 | 0.220 |
Why?
| | Receptors, Opioid, mu | 1 | 2024 | 74 | 0.220 |
Why?
| | Cells, Cultured | 12 | 2020 | 4192 | 0.210 |
Why?
| | Morphine | 1 | 2024 | 158 | 0.200 |
Why?
| | Amino Acids | 1 | 2007 | 497 | 0.200 |
Why?
| | Transcription Factors | 3 | 2005 | 1718 | 0.200 |
Why?
| | Immunoglobulins | 2 | 2024 | 171 | 0.200 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2004 | 368 | 0.200 |
Why?
| | Receptors, Complement 3d | 1 | 2023 | 141 | 0.200 |
Why?
| | Blood-Retinal Barrier | 2 | 2012 | 15 | 0.190 |
Why?
| | Dextrans | 2 | 2024 | 84 | 0.190 |
Why?
| | Mitogens | 2 | 1999 | 61 | 0.190 |
Why?
| | Models, Biological | 2 | 2019 | 1773 | 0.190 |
Why?
| | Lectins | 2 | 2019 | 49 | 0.170 |
Why?
| | Single-Chain Antibodies | 1 | 2020 | 18 | 0.170 |
Why?
| | Synoviocytes | 1 | 2020 | 16 | 0.170 |
Why?
| | Saccharomyces cerevisiae | 1 | 2025 | 556 | 0.170 |
Why?
| | Humans | 37 | 2025 | 136750 | 0.170 |
Why?
| | Repressor Proteins | 2 | 2019 | 427 | 0.160 |
Why?
| | Scavenger Receptors, Class A | 1 | 2019 | 12 | 0.160 |
Why?
| | Joints | 1 | 2020 | 105 | 0.160 |
Why?
| | Leukocytes | 2 | 2019 | 311 | 0.160 |
Why?
| | Macrophages, Peritoneal | 1 | 2019 | 94 | 0.160 |
Why?
| | Cell-Derived Microparticles | 1 | 2020 | 71 | 0.160 |
Why?
| | CD55 Antigens | 1 | 2019 | 30 | 0.160 |
Why?
| | Collagen Type II | 1 | 2019 | 53 | 0.150 |
Why?
| | Recombinant Fusion Proteins | 5 | 2023 | 664 | 0.150 |
Why?
| | Protein Corona | 1 | 2019 | 6 | 0.150 |
Why?
| | Immunoglobulin M | 1 | 2020 | 288 | 0.150 |
Why?
| | Opsonin Proteins | 1 | 2019 | 25 | 0.150 |
Why?
| | Calcium Phosphates | 1 | 1998 | 26 | 0.150 |
Why?
| | Complement Pathway, Alternative | 1 | 2020 | 122 | 0.150 |
Why?
| | Bone Marrow | 1 | 2020 | 286 | 0.150 |
Why?
| | RNA Interference | 2 | 2020 | 466 | 0.150 |
Why?
| | Recombinant Proteins | 5 | 2008 | 1350 | 0.150 |
Why?
| | Lymphocytes | 1 | 2020 | 393 | 0.140 |
Why?
| | Intravital Microscopy | 1 | 2017 | 25 | 0.140 |
Why?
| | Protein Kinase C | 1 | 1998 | 261 | 0.140 |
Why?
| | Biological Transport | 5 | 2020 | 416 | 0.140 |
Why?
| | Monocytes | 1 | 2020 | 563 | 0.140 |
Why?
| | Gene Expression | 3 | 2020 | 1500 | 0.140 |
Why?
| | Transfection | 5 | 2020 | 941 | 0.140 |
Why?
| | Glycosylation | 2 | 2008 | 151 | 0.130 |
Why?
| | Antibodies | 1 | 2019 | 411 | 0.130 |
Why?
| | Protein Binding | 6 | 2024 | 2216 | 0.130 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2017 | 127 | 0.130 |
Why?
| | Neutrophils | 2 | 2020 | 1236 | 0.130 |
Why?
| | Mice, Inbred BALB C | 4 | 2021 | 1269 | 0.130 |
Why?
| | Mice, Knockout | 5 | 2020 | 3009 | 0.130 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2024 | 2184 | 0.130 |
Why?
| | Inflammation Mediators | 1 | 2019 | 513 | 0.130 |
Why?
| | Bone Marrow Cells | 3 | 2020 | 316 | 0.120 |
Why?
| | Autoantibodies | 1 | 2023 | 1496 | 0.120 |
Why?
| | Dogs | 3 | 2025 | 411 | 0.120 |
Why?
| | Mice, Inbred DBA | 2 | 2020 | 200 | 0.120 |
Why?
| | Complement C5 | 1 | 2015 | 81 | 0.120 |
Why?
| | Antibodies, Anti-Idiotypic | 1 | 2015 | 59 | 0.120 |
Why?
| | Receptor, Anaphylatoxin C5a | 1 | 2015 | 30 | 0.120 |
Why?
| | Mice, Inbred C57BL | 7 | 2021 | 5750 | 0.110 |
Why?
| | Rats, Inbred F344 | 3 | 2004 | 264 | 0.110 |
Why?
| | Membrane Glycoproteins | 3 | 2002 | 500 | 0.110 |
Why?
| | Drug Delivery Systems | 2 | 2020 | 362 | 0.110 |
Why?
| | Macromolecular Substances | 3 | 2005 | 229 | 0.100 |
Why?
| | Kinetics | 5 | 2017 | 1664 | 0.100 |
Why?
| | Salicylic Acid | 1 | 2012 | 9 | 0.100 |
Why?
| | Melanins | 1 | 2012 | 18 | 0.100 |
Why?
| | Pigment Epithelium of Eye | 1 | 2012 | 35 | 0.100 |
Why?
| | Skin | 1 | 2017 | 751 | 0.100 |
Why?
| | Chloroquine | 1 | 2012 | 52 | 0.100 |
Why?
| | Enzyme Activation | 2 | 2006 | 810 | 0.100 |
Why?
| | RNA, Messenger | 6 | 2025 | 2831 | 0.100 |
Why?
| | Electric Impedance | 1 | 2012 | 107 | 0.100 |
Why?
| | Sodium Channels | 2 | 1989 | 65 | 0.100 |
Why?
| | Precipitin Tests | 4 | 2002 | 100 | 0.090 |
Why?
| | Leukostasis | 1 | 2011 | 3 | 0.090 |
Why?
| | Polyglycolic Acid | 1 | 2011 | 43 | 0.090 |
Why?
| | Tyrosine | 1 | 2012 | 222 | 0.090 |
Why?
| | Neoplasm Proteins | 2 | 2008 | 434 | 0.090 |
Why?
| | Transcription Factor RelA | 4 | 1995 | 87 | 0.090 |
Why?
| | Drug Stability | 1 | 2011 | 167 | 0.090 |
Why?
| | Macular Edema | 1 | 2011 | 43 | 0.090 |
Why?
| | Inflammation | 2 | 2024 | 2835 | 0.090 |
Why?
| | NF-KappaB Inhibitor alpha | 4 | 2002 | 54 | 0.090 |
Why?
| | Capillary Permeability | 1 | 2011 | 145 | 0.090 |
Why?
| | Drug Discovery | 1 | 2012 | 141 | 0.090 |
Why?
| | Retinal Pigment Epithelium | 1 | 2011 | 77 | 0.090 |
Why?
| | Chemokine CXCL9 | 1 | 2010 | 27 | 0.090 |
Why?
| | Gene Silencing | 1 | 2011 | 195 | 0.090 |
Why?
| | Chemokine CXCL10 | 1 | 2010 | 39 | 0.090 |
Why?
| | HeLa Cells | 4 | 2002 | 633 | 0.090 |
Why?
| | Immunosuppressive Agents | 1 | 1995 | 889 | 0.080 |
Why?
| | Glucocorticoids | 3 | 2000 | 593 | 0.080 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2011 | 195 | 0.080 |
Why?
| | Lactic Acid | 1 | 2011 | 305 | 0.080 |
Why?
| | Intracellular Signaling Peptides and Proteins | 2 | 2005 | 455 | 0.080 |
Why?
| | Oligopeptides | 1 | 2011 | 271 | 0.080 |
Why?
| | Base Sequence | 5 | 2005 | 2179 | 0.080 |
Why?
| | Genetic Therapy | 1 | 2011 | 293 | 0.080 |
Why?
| | Interleukin-10 | 1 | 2011 | 302 | 0.080 |
Why?
| | Diabetic Retinopathy | 1 | 2011 | 189 | 0.080 |
Why?
| | Cell Line | 5 | 2011 | 2838 | 0.080 |
Why?
| | Radiation Chimera | 1 | 2009 | 30 | 0.080 |
Why?
| | Phospholipases A2, Cytosolic | 1 | 2009 | 7 | 0.080 |
Why?
| | Flow Cytometry | 2 | 2025 | 1180 | 0.080 |
Why?
| | Radiation Injuries, Experimental | 1 | 2009 | 22 | 0.080 |
Why?
| | Genes | 1 | 1989 | 230 | 0.080 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2008 | 1396 | 0.080 |
Why?
| | Molecular Sequence Data | 5 | 2005 | 2894 | 0.080 |
Why?
| | Magnetite Nanoparticles | 2 | 2019 | 30 | 0.070 |
Why?
| | Bone Resorption | 1 | 2009 | 86 | 0.070 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2011 | 434 | 0.070 |
Why?
| | Immunoglobulin G | 2 | 2025 | 887 | 0.070 |
Why?
| | Pyrimidines | 1 | 2011 | 470 | 0.070 |
Why?
| | Cell Nucleus | 4 | 2004 | 617 | 0.070 |
Why?
| | Sulfonamides | 1 | 2011 | 513 | 0.070 |
Why?
| | Bone Marrow Transplantation | 1 | 2009 | 287 | 0.070 |
Why?
| | Tuberculosis | 1 | 2010 | 279 | 0.070 |
Why?
| | Blotting, Western | 3 | 2011 | 1225 | 0.070 |
Why?
| | Mycobacterium tuberculosis | 1 | 2010 | 312 | 0.070 |
Why?
| | Peptide Fragments | 1 | 2011 | 705 | 0.070 |
Why?
| | Chromosome Mapping | 2 | 2005 | 523 | 0.070 |
Why?
| | Tumor Cells, Cultured | 5 | 2002 | 953 | 0.070 |
Why?
| | Cricetulus | 1 | 2007 | 109 | 0.070 |
Why?
| | Disease Progression | 2 | 2012 | 2751 | 0.070 |
Why?
| | CHO Cells | 1 | 2007 | 161 | 0.070 |
Why?
| | Protein Conformation | 2 | 2019 | 933 | 0.070 |
Why?
| | Cricetinae | 1 | 2007 | 289 | 0.060 |
Why?
| | Male | 11 | 2025 | 67305 | 0.060 |
Why?
| | CD5 Antigens | 1 | 2006 | 10 | 0.060 |
Why?
| | Rats, Mutant Strains | 1 | 2006 | 25 | 0.060 |
Why?
| | Thymus Gland | 2 | 2005 | 313 | 0.060 |
Why?
| | Antineoplastic Agents | 1 | 2017 | 2123 | 0.060 |
Why?
| | Disease Models, Animal | 2 | 2019 | 4281 | 0.060 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2008 | 2051 | 0.060 |
Why?
| | Genes, Synthetic | 1 | 2005 | 15 | 0.060 |
Why?
| | Protein Kinase Inhibitors | 1 | 2011 | 916 | 0.060 |
Why?
| | Self Tolerance | 1 | 2005 | 28 | 0.060 |
Why?
| | Two-Hybrid System Techniques | 1 | 2005 | 59 | 0.060 |
Why?
| | Autoantigens | 2 | 2005 | 428 | 0.060 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 2005 | 155 | 0.060 |
Why?
| | Zinc Fingers | 1 | 2005 | 50 | 0.060 |
Why?
| | Epithelial Cells | 1 | 2011 | 1094 | 0.060 |
Why?
| | Membrane Proteins | 2 | 2004 | 1163 | 0.060 |
Why?
| | Ferric Compounds | 1 | 2025 | 56 | 0.060 |
Why?
| | COS Cells | 1 | 2005 | 188 | 0.060 |
Why?
| | L-Selectin | 1 | 2004 | 26 | 0.060 |
Why?
| | Stromal Cells | 1 | 2005 | 112 | 0.060 |
Why?
| | DNA, Complementary | 1 | 2005 | 271 | 0.060 |
Why?
| | Protein Interaction Mapping | 1 | 2005 | 109 | 0.060 |
Why?
| | Gene Deletion | 1 | 2006 | 389 | 0.060 |
Why?
| | Cell Culture Techniques | 1 | 2007 | 362 | 0.060 |
Why?
| | Lipopolysaccharides | 2 | 2020 | 886 | 0.050 |
Why?
| | Rheumatoid Factor | 1 | 2025 | 175 | 0.050 |
Why?
| | MAP Kinase Signaling System | 1 | 2006 | 320 | 0.050 |
Why?
| | Corticosterone | 1 | 2005 | 236 | 0.050 |
Why?
| | Antigen Presentation | 1 | 2005 | 216 | 0.050 |
Why?
| | Middle Aged | 6 | 2025 | 33225 | 0.050 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2005 | 176 | 0.050 |
Why?
| | Phosphorylation | 3 | 2002 | 1758 | 0.050 |
Why?
| | Cell Line, Tumor | 2 | 2009 | 3406 | 0.050 |
Why?
| | Computer Simulation | 1 | 2008 | 973 | 0.050 |
Why?
| | 1-Carboxyglutamic Acid | 1 | 1983 | 4 | 0.050 |
Why?
| | Carrier Proteins | 2 | 2005 | 769 | 0.050 |
Why?
| | Glutamates | 1 | 1983 | 59 | 0.050 |
Why?
| | Arteriosclerosis | 1 | 1983 | 88 | 0.050 |
Why?
| | Interleukin-6 | 2 | 2009 | 778 | 0.050 |
Why?
| | Heart Valves | 1 | 1983 | 43 | 0.050 |
Why?
| | Receptors, Antigen, T-Cell | 2 | 2004 | 718 | 0.050 |
Why?
| | Immune Sera | 1 | 2002 | 88 | 0.050 |
Why?
| | Phosphoserine | 1 | 2002 | 34 | 0.050 |
Why?
| | Protein Structure, Tertiary | 1 | 2005 | 860 | 0.050 |
Why?
| | I-kappa B Kinase | 1 | 2002 | 55 | 0.050 |
Why?
| | Kupffer Cells | 1 | 2002 | 50 | 0.050 |
Why?
| | Blood Proteins | 2 | 2011 | 252 | 0.050 |
Why?
| | Gene Products, tat | 1 | 2002 | 23 | 0.050 |
Why?
| | E-Selectin | 1 | 2002 | 57 | 0.050 |
Why?
| | Down-Regulation | 1 | 2004 | 656 | 0.050 |
Why?
| | Cytosol | 1 | 2002 | 226 | 0.050 |
Why?
| | HEK293 Cells | 1 | 2024 | 729 | 0.050 |
Why?
| | Etoposide | 1 | 2002 | 158 | 0.050 |
Why?
| | Calcium-Binding Proteins | 1 | 1983 | 218 | 0.050 |
Why?
| | Aldehydes | 1 | 2002 | 145 | 0.050 |
Why?
| | Rats, Long-Evans | 1 | 2021 | 125 | 0.040 |
Why?
| | Protein Isoforms | 1 | 2002 | 403 | 0.040 |
Why?
| | Calcinosis | 1 | 1983 | 235 | 0.040 |
Why?
| | Severity of Illness Index | 1 | 2009 | 2819 | 0.040 |
Why?
| | Dendritic Cells | 1 | 2004 | 484 | 0.040 |
Why?
| | NF-kappa B p50 Subunit | 3 | 1995 | 26 | 0.040 |
Why?
| | Thymocytes | 1 | 2020 | 35 | 0.040 |
Why?
| | Homeostasis | 1 | 2004 | 619 | 0.040 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2000 | 162 | 0.040 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2020 | 106 | 0.040 |
Why?
| | Adult | 5 | 2025 | 37626 | 0.040 |
Why?
| | Bone and Bones | 1 | 1983 | 316 | 0.040 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2020 | 80 | 0.040 |
Why?
| | Hematinics | 1 | 2019 | 22 | 0.040 |
Why?
| | Protein Biosynthesis | 1 | 2002 | 430 | 0.040 |
Why?
| | Phytohemagglutinins | 1 | 1999 | 30 | 0.040 |
Why?
| | Ionomycin | 1 | 1999 | 23 | 0.040 |
Why?
| | Fas Ligand Protein | 1 | 1999 | 59 | 0.040 |
Why?
| | Complement C3-C5 Convertases | 1 | 2019 | 24 | 0.040 |
Why?
| | Proto-Oncogene Proteins | 2 | 1993 | 647 | 0.040 |
Why?
| | Hybridomas | 1 | 1999 | 237 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-jun | 1 | 1998 | 55 | 0.040 |
Why?
| | Durapatite | 1 | 1998 | 37 | 0.040 |
Why?
| | 3T3 Cells | 1 | 1998 | 163 | 0.040 |
Why?
| | Female | 7 | 2025 | 72785 | 0.040 |
Why?
| | B-Lymphocytes | 1 | 2004 | 846 | 0.040 |
Why?
| | Fluorescent Dyes | 1 | 2020 | 317 | 0.040 |
Why?
| | Tumor Suppressor Proteins | 1 | 2001 | 327 | 0.040 |
Why?
| | Gene Expression Regulation | 3 | 1993 | 2605 | 0.040 |
Why?
| | Joint Diseases | 1 | 1998 | 60 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-fos | 1 | 1998 | 185 | 0.040 |
Why?
| | Carcinoma, Renal Cell | 1 | 2000 | 215 | 0.040 |
Why?
| | Chloramphenicol O-Acetyltransferase | 2 | 1995 | 38 | 0.040 |
Why?
| | Gene Expression Profiling | 1 | 2005 | 1772 | 0.040 |
Why?
| | Lung Neoplasms | 2 | 2009 | 2489 | 0.030 |
Why?
| | Collectins | 1 | 2017 | 12 | 0.030 |
Why?
| | Cartilage | 1 | 2019 | 188 | 0.030 |
Why?
| | Diabetes Mellitus | 1 | 2006 | 1033 | 0.030 |
Why?
| | Binding Sites | 1 | 2000 | 1301 | 0.030 |
Why?
| | Injections, Intravenous | 1 | 2017 | 207 | 0.030 |
Why?
| | Antigen-Antibody Complex | 1 | 2017 | 90 | 0.030 |
Why?
| | Brain | 1 | 1989 | 2664 | 0.030 |
Why?
| | Camptothecin | 1 | 2017 | 115 | 0.030 |
Why?
| | Tissue Distribution | 1 | 2017 | 330 | 0.030 |
Why?
| | Drug Synergism | 2 | 1995 | 383 | 0.030 |
Why?
| | Mannose-Binding Lectin | 1 | 2016 | 23 | 0.030 |
Why?
| | Cell Cycle Proteins | 1 | 2001 | 613 | 0.030 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 1998 | 366 | 0.030 |
Why?
| | Aged | 3 | 2025 | 23800 | 0.030 |
Why?
| | Proteins | 1 | 1983 | 1009 | 0.030 |
Why?
| | Surface Properties | 1 | 2017 | 412 | 0.030 |
Why?
| | Receptors, Steroid | 1 | 1996 | 50 | 0.030 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2017 | 190 | 0.030 |
Why?
| | Cloning, Molecular | 3 | 2002 | 534 | 0.030 |
Why?
| | Analgesics, Opioid | 1 | 2024 | 991 | 0.030 |
Why?
| | Particle Size | 1 | 2017 | 391 | 0.030 |
Why?
| | Kidney Neoplasms | 1 | 2000 | 401 | 0.030 |
Why?
| | Cytoplasm | 2 | 1993 | 272 | 0.030 |
Why?
| | Proteolysis | 1 | 2016 | 177 | 0.030 |
Why?
| | HIV-1 | 1 | 2002 | 862 | 0.030 |
Why?
| | Viral Matrix Proteins | 1 | 1995 | 30 | 0.030 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 2 | 2010 | 283 | 0.030 |
Why?
| | Endothelium, Vascular | 1 | 2002 | 926 | 0.030 |
Why?
| | RNA-Binding Proteins | 1 | 2019 | 423 | 0.030 |
Why?
| | Mifepristone | 1 | 1995 | 64 | 0.030 |
Why?
| | Enhancer Elements, Genetic | 1 | 1996 | 190 | 0.030 |
Why?
| | Collagen | 1 | 2017 | 446 | 0.030 |
Why?
| | Glutathione Transferase | 1 | 1995 | 105 | 0.030 |
Why?
| | Androgens | 1 | 1996 | 187 | 0.030 |
Why?
| | Herpesvirus 4, Human | 1 | 1995 | 167 | 0.030 |
Why?
| | NF-kappa B p52 Subunit | 1 | 1993 | 1 | 0.030 |
Why?
| | Up-Regulation | 2 | 2010 | 844 | 0.030 |
Why?
| | Promoter Regions, Genetic | 2 | 2002 | 1249 | 0.030 |
Why?
| | Fibroblasts | 1 | 1998 | 993 | 0.030 |
Why?
| | Monophenol Monooxygenase | 1 | 2012 | 8 | 0.030 |
Why?
| | Madin Darby Canine Kidney Cells | 1 | 2012 | 14 | 0.030 |
Why?
| | Levodopa | 1 | 2012 | 30 | 0.020 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 2 | 2004 | 47 | 0.020 |
Why?
| | Cell Membrane Permeability | 1 | 2012 | 78 | 0.020 |
Why?
| | Protein Precursors | 1 | 1993 | 132 | 0.020 |
Why?
| | Pigmentation | 1 | 2012 | 52 | 0.020 |
Why?
| | Immunoenzyme Techniques | 1 | 2012 | 219 | 0.020 |
Why?
| | Transcriptional Activation | 2 | 2010 | 378 | 0.020 |
Why?
| | Plasmids | 2 | 1992 | 360 | 0.020 |
Why?
| | DNA | 2 | 2002 | 1458 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2001 | 2412 | 0.020 |
Why?
| | Microscopy, Phase-Contrast | 1 | 2011 | 18 | 0.020 |
Why?
| | Administration, Ophthalmic | 1 | 2011 | 15 | 0.020 |
Why?
| | Rhodopsin | 1 | 2011 | 11 | 0.020 |
Why?
| | Rats, Inbred BN | 1 | 2011 | 58 | 0.020 |
Why?
| | Protein Tyrosine Phosphatases | 2 | 2004 | 172 | 0.020 |
Why?
| | TNF-Related Apoptosis-Inducing Ligand | 2 | 2002 | 51 | 0.020 |
Why?
| | Ophthalmic Solutions | 1 | 2011 | 75 | 0.020 |
Why?
| | Knee Joint | 1 | 2015 | 409 | 0.020 |
Why?
| | Liver | 1 | 2020 | 1940 | 0.020 |
Why?
| | Indazoles | 1 | 2011 | 69 | 0.020 |
Why?
| | Interleukin-1 | 1 | 1995 | 964 | 0.020 |
Why?
| | Blotting, Northern | 1 | 2010 | 200 | 0.020 |
Why?
| | Vitreous Body | 1 | 2011 | 110 | 0.020 |
Why?
| | Chromatography, Liquid | 1 | 2012 | 432 | 0.020 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2011 | 346 | 0.020 |
Why?
| | Apoptosis Regulatory Proteins | 2 | 2002 | 188 | 0.020 |
Why?
| | Antibody Formation | 1 | 1972 | 298 | 0.020 |
Why?
| | Microscopy, Confocal | 1 | 2011 | 324 | 0.020 |
Why?
| | Saxitoxin | 1 | 1989 | 3 | 0.020 |
Why?
| | Tandem Mass Spectrometry | 1 | 2012 | 531 | 0.020 |
Why?
| | Cell Membrane | 1 | 2012 | 735 | 0.020 |
Why?
| | Embryonic and Fetal Development | 1 | 1988 | 97 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 975 | 0.020 |
Why?
| | Molecular Targeted Therapy | 1 | 2011 | 411 | 0.020 |
Why?
| | Dinoprostone | 1 | 2009 | 191 | 0.020 |
Why?
| | Cell Survival | 1 | 2011 | 1116 | 0.020 |
Why?
| | Retinal Ganglion Cells | 1 | 1988 | 110 | 0.020 |
Why?
| | Body Weight | 1 | 2011 | 985 | 0.020 |
Why?
| | Saccharomyces | 1 | 1986 | 8 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2009 | 657 | 0.020 |
Why?
| | Retina | 1 | 1988 | 298 | 0.020 |
Why?
| | Kidney | 1 | 2012 | 1467 | 0.010 |
Why?
| | Oligodeoxyribonucleotides | 2 | 1996 | 143 | 0.010 |
Why?
| | Receptor-Like Protein Tyrosine Phosphatases, Class 8 | 1 | 2004 | 63 | 0.010 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2001 | 3710 | 0.010 |
Why?
| | Antigen-Presenting Cells | 1 | 2004 | 156 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2011 | 2476 | 0.010 |
Why?
| | Proto-Oncogene Proteins c-rel | 2 | 1993 | 9 | 0.010 |
Why?
| | Osteocalcin | 1 | 1983 | 37 | 0.010 |
Why?
| | Vitamin K | 1 | 1983 | 44 | 0.010 |
Why?
| | Depression, Chemical | 1 | 2002 | 23 | 0.010 |
Why?
| | Biotransformation | 1 | 2002 | 65 | 0.010 |
Why?
| | Adenoviridae Infections | 1 | 2002 | 17 | 0.010 |
Why?
| | Mice, Inbred NOD | 1 | 2004 | 600 | 0.010 |
Why?
| | tat Gene Products, Human Immunodeficiency Virus | 1 | 2002 | 24 | 0.010 |
Why?
| | DNA Fingerprinting | 1 | 2002 | 26 | 0.010 |
Why?
| | Culture Media | 1 | 2002 | 165 | 0.010 |
Why?
| | Electrophoretic Mobility Shift Assay | 1 | 2002 | 85 | 0.010 |
Why?
| | Blood Glucose | 1 | 2011 | 2181 | 0.010 |
Why?
| | Oligonucleotides | 1 | 2002 | 148 | 0.010 |
Why?
| | Rats, Inbred BB | 1 | 2001 | 6 | 0.010 |
Why?
| | Thy-1 Antigens | 1 | 2001 | 11 | 0.010 |
Why?
| | Proliferating Cell Nuclear Antigen | 1 | 2001 | 53 | 0.010 |
Why?
| | Rats, Inbred Lew | 1 | 2001 | 114 | 0.010 |
Why?
| | MAP Kinase Kinase 4 | 1 | 2000 | 29 | 0.010 |
Why?
| | Caspase 8 | 1 | 2000 | 48 | 0.010 |
Why?
| | CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2000 | 22 | 0.010 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2001 | 75 | 0.010 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 1 | 2001 | 46 | 0.010 |
Why?
| | Caspase 9 | 1 | 2000 | 57 | 0.010 |
Why?
| | Chromosome Segregation | 1 | 2001 | 47 | 0.010 |
Why?
| | Lymphopenia | 1 | 2001 | 62 | 0.010 |
Why?
| | Time Factors | 1 | 2011 | 6808 | 0.010 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 2000 | 134 | 0.010 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2000 | 195 | 0.010 |
Why?
| | Cyclin-Dependent Kinases | 1 | 2001 | 132 | 0.010 |
Why?
| | Caspases | 1 | 2000 | 247 | 0.010 |
Why?
| | Immunophenotyping | 1 | 2001 | 319 | 0.010 |
Why?
| | Microtubule-Associated Proteins | 1 | 2001 | 194 | 0.010 |
Why?
| | Vitamin D | 1 | 1983 | 397 | 0.010 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2000 | 313 | 0.010 |
Why?
| | Cell Lineage | 1 | 2001 | 347 | 0.010 |
Why?
| | Aging | 1 | 1989 | 1863 | 0.010 |
Why?
| | Ligands | 1 | 2000 | 661 | 0.010 |
Why?
| | Cell Cycle | 1 | 2001 | 601 | 0.010 |
Why?
| | Enzyme Inhibitors | 1 | 2001 | 839 | 0.010 |
Why?
| | Consensus Sequence | 1 | 1996 | 73 | 0.010 |
Why?
| | Complement C4 | 1 | 1996 | 28 | 0.010 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2002 | 683 | 0.010 |
Why?
| | Cell Movement | 1 | 2001 | 968 | 0.010 |
Why?
| | Mutagenesis, Site-Directed | 1 | 1996 | 374 | 0.010 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2000 | 800 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2001 | 2486 | 0.010 |
Why?
| | Cytokines | 1 | 2002 | 2084 | 0.010 |
Why?
| | Insulin | 1 | 2004 | 2406 | 0.010 |
Why?
| | Transcription Factor RelB | 1 | 1992 | 4 | 0.010 |
Why?
| | Hemolytic Plaque Technique | 1 | 1972 | 29 | 0.010 |
Why?
| | Agar | 1 | 1972 | 12 | 0.010 |
Why?
| | Splenomegaly | 1 | 1972 | 15 | 0.010 |
Why?
| | Freund's Adjuvant | 1 | 1972 | 18 | 0.010 |
Why?
| | Culture Techniques | 1 | 1972 | 81 | 0.010 |
Why?
| | Vinblastine | 1 | 1972 | 70 | 0.010 |
Why?
| | Mutagenesis | 1 | 1992 | 179 | 0.010 |
Why?
| | Fluorescent Antibody Technique | 1 | 1992 | 388 | 0.010 |
Why?
| | Chickens | 1 | 1972 | 191 | 0.010 |
Why?
| | Clone Cells | 1 | 1972 | 266 | 0.010 |
Why?
| | Organ Size | 1 | 1972 | 477 | 0.010 |
Why?
| | Alternative Splicing | 1 | 1992 | 229 | 0.010 |
Why?
| | Rabbits | 1 | 1972 | 792 | 0.010 |
Why?
| | Cell Division | 1 | 1972 | 796 | 0.010 |
Why?
| | Antigens | 1 | 1972 | 358 | 0.010 |
Why?
| | Spleen | 1 | 1972 | 514 | 0.010 |
Why?
| | Breast Neoplasms | 1 | 2002 | 2234 | 0.000 |
Why?
| | Cattle | 1 | 1972 | 981 | 0.000 |
Why?
| | Sheep | 1 | 1972 | 855 | 0.000 |
Why?
| | Child, Preschool | 1 | 1983 | 10997 | 0.000 |
Why?
| | DNA, Fungal | 1 | 1986 | 80 | 0.000 |
Why?
| | Erythrocytes | 1 | 1972 | 699 | 0.000 |
Why?
| | Immunohistochemistry | 1 | 1988 | 1733 | 0.000 |
Why?
| | Child | 1 | 1983 | 21816 | 0.000 |
Why?
|
|
Scheinman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|